Could Tempus AI’s (TEM) New Research Collaboration Reveal Its Edge in Data-Driven Oncology?

• Tempus AI, Inc. recently announced a multi-year research collaboration with the Institute for Follicular Lymphoma Innovation to generate comprehensive multi-omic datasets for follicular lymphoma research.
• This marks Tempus' first study partnership with a non-profit foundation, aiming to accelerate precision medicine and the discovery of new biomarkers in a disease with significant treatment challenges.
• We'll explore how Tempus AI’s expanded partnership in follicular lymphoma research could impact its outlook in cancer genomics and data-driven healthcare.

Find companies with promising cash flow potential yet trading below their fair value.

Tempus AI Investment Narrative Recap

To own shares in Tempus AI, you’d need to believe that scaling advanced data collaborations can keep the company at the center of innovation in cancer genomics and precision medicine. This new research partnership with the Institute for Follicular Lymphoma Innovation showcases Tempus’ efforts to deepen its multi-omic data assets, a key long-term catalyst, but in the near term, the company’s largest risk remains persistent unprofitability and the pressure of rising R&D costs outpacing revenue.

The recent collaboration with Whitehawk Therapeutics, focused on leveraging Tempus' real-world data for oncology research, ties back to the ongoing priority for monetizing data at scale; such partnerships build on Tempus’ position as a data-driven partner for biotech and pharma, supporting its revenue growth ambitions but still facing challenges in translating innovation into sustainable margins and positive cash flow.

Yet, in contrast, there’s also increasing competition and margin pressure that investors should be aware of as Tempus seeks to expand its role…

Read the full narrative on Tempus AI (it's free!)

Tempus AI's outlook anticipates $2.1 billion in revenue and $295.0 million in earnings by 2028. Achieving these targets would require a 29.7% annual revenue growth rate and a $494.7 million increase in earnings from the current level of -$199.7 million.

Uncover how Tempus AI's forecasts yield a $87.17 fair value, a 24% upside to its current price.

Exploring Other Perspectives

Fair value estimates from 32 Simply Wall St Community members for Tempus AI range from US$25.24 to US$151.72 per share. While many see upside, persistent operating losses and the company’s need for sustained revenue gains are central to any outlook on future returns, consider reviewing these diverse community viewpoints before making up your mind.

Explore 32 other fair value estimates on Tempus AI - why the stock might be worth over 2x more than the current price!

Build Your Own Tempus AI Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Tempus AI research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Tempus AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tempus AI's overall financial health at a glance.

Contemplating Other Strategies?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com